Despite the emergence of new drugs for the topical treatment of rosacea in recent years and the existence of a wide range of dermocosmetic products, no major advances have been made in the systemic treatment of this disease in several decades. Accordingly, many patients, and particularly those with more severe forms of rosacea, have difficulty achieving good disease control. Considering that rosacea is a common disease and can have a psychological impact on patients, we need to explore new treatment alternatives.

The use of azithromycin in rosacea is recent, even though this antibiotic has been on the market for over 20 years.1 As is often the case with dermatological disorders, there is a shortage of well-designed studies for clarifying the efficacy of azithromycin in rosacea and establishing optimal treatment regimens. Accordingly, initiatives like the present study are very welcome.

Azithromycin has a good safety profile and can also be used during pregnancy.2 It is therefore an interesting option to consider in the management of rosacea. We hope that this study provides an impetus for further improvements in this disease.